Cannabidivarin

Cannabidivarin is a non-intoxicating psychoactive cannabinoid found in Cannabis. It is a homolog (chemistry) of cannabidiol, with the side-chain shortened by two methylene bridges.
Although cannabidivarin is usually a minor constituent of the cannabinoid profile, enhanced levels of CBDV have been reported in feral populations of C. indica from northwest India, and in hashish from Nepal.
CBDV demonstrated anticonvulsant in rodent models in a single published study. It was identified for the first time in 1969 by Vollner et al.
Similarly to CBD, it has seven double bond isomers and 30 stereoisomers. It is not scheduled by Convention on Psychotropic Substances. It is being actively developed by GW Pharmaceuticals because of a demonstrated neurochemical pathway for previously observed anti-epileptic and anti-convulsive action. GW has begun several Phase-2 trials for adult epilepsy, for childhood epilepsy and for Prader-Willi Syndrome.